Lung Cancer

Patients with advanced KRAS^G12C harboring NSCLC maintained quality of life and physical functioning with tolerable side effects while being treated with sotorasib.

Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.

A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.

Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRAS^G12C-mutated NSCLC.

The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.

Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.

Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.

An investigational treatment for second-line treatment of NSCLC was found to be well tolerated and active against KRAS mutations, according to the results of a new study.

To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.